Forte Biosciences, Inc. (FBRX): Valuation
TTM figures as of June 30, 2026
Forte Biosciences, Inc. trades at a -4.41% free-cash-flow yield. That FCF yield is higher than 90% of its own month-end history back to 2017.
Earnings yield -5.38%.
113 month-end valuation observations are on file, starting April 2017.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is FBRX cheap versus its own history?
Forte Biosciences, Inc. trades at a -4.41% free-cash-flow yield. That FCF yield is higher than 90% of its own month-end history back to 2017.
What is FBRX's free-cash-flow yield?
Forte Biosciences, Inc. currently yields -4.41% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.